Helping patients stay on their treatment path longer
Kinase inhibitors eventually develop resistance. Our drug candidates are structurally different and address the key limitations of existing therapies.
Founded and Led by Pioneers of Precision Medicine
Turning Point Therapeutics has assembled an experienced team to discover and develop next-generation cancer treatments with greater potency and potentially improved efficacy over existing kinase inhibitors.
Clear Potential to Improve Cancer Treatment
Our lead drug candidate, repotrectinib, is expected to enter a registration-enabling study in the second half of 2019 in non-small cell lung cancer and advanced solid tumors harboring oncogenic driver fusions.
We believe we’ve discovered a way to overcome one of the greatest limitations of today’s targeted cancer treatments, and we’re working to bring it to patients as quickly as possible.
-Athena Countouriotis, M.D., President and CEO